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Thenappan Chandrasekar1, Joy C. Yang1, Allen C. Gao1 and Christopher P. Evans1,2*Abstract
Multiple mechanisms of resistance contribute to the inevitable progression of hormone-sensitive prostate cancer to
castration-resistant prostate cancer (CRPC). Currently approved therapies for CRPC include systemic chemotherapy
(docetaxel and cabazitaxel) and agents targeting the resistance pathways leading to CRPC, including enzalutamide
and abiraterone. While there is significant survival benefit, primary and secondary resistance to these therapies
develops rapidly. Up to one-third of patients have primary resistance to enzalutamide and abiraterone; the remaining
patients eventually progress on treatment. Understanding the mechanisms of resistance resulting in progression as
well as identifying new targetable pathways remains the focus of current prostate cancer research. We review current
knowledge of mechanisms of resistance to the currently approved treatments, development of adjunctive therapies,
and identification of new pathways being targeted for therapeutic purposes.
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Prostate adenocarcinoma is the second-leading cause of
cancer-related deaths and is the most commonly diag-
nosed non-cutaneous malignancy in men [1, 2]. Despite
the focus on screening and early detection of prostate
cancer, approximately 20 % of men continue to present
with advanced or metastatic disease [3], and there were
more than 29,000 prostate cancer-related deaths in the
United States in 2014 alone [1].
The androgen axis is an important component of pros-
tate cancer physiology. The androgen receptor (AR) is a
110 kDa nuclear receptor encoded by the AR gene,
which is on Xq11-12 and has eight exons. It is part of a
family that includes the mineralocorticoid, glucocorticoid,
estrogen, and progesterone receptors. It has four func-
tional motifs – the amino-terminal domain (N-terminal
domain, NTD), DNA binding domain, hinge region, and
ligand-binding domain (LBD) [4, 5]. It is bound by heat-
shock proteins in the inactive state in the cytoplasm, until
androgen binding to the LBD causes a conformational
change that leads to heat-shock protein disassociation,
homodimerization of the receptor, and subsequent nu-
clear translocation. In the nucleus, it binds to androgen-* Correspondence: cpevans@ucdavis.edu
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regulated genes [6, 7]. Androgens, specifically testoster-
one, the primary circulating androgen produced mainly in
the Leydig cells in the testis and minimally in the adrenal
cortex, and dihydrotestosterone (DHT), are the major
ligands for AR. DHT, which is formed by 5α-reductase
activity on testosterone within the cytoplasm, is the main
functionally active ligand in the prostate microenviron-
ment, and has a 5-fold higher affinity for the LBD of AR
than testosterone [8–10].
In patients who are diagnosed with or progress to
advanced or metastatic prostate cancer, the treatment
standard is currently androgen-deprivation therapy (ADT).
First described by Huggins and Hodges in a dog model
[11], ADT now is achieved through either surgical
(bilateral orchiectomy) or medical castration. Medical
castration utilizes different classes of agents, including
LHRH agonists, LHRH antagonists, and anti-androgens.
However, despite an initial benefit, the majority of patients
will progress to castration-resistant disease within 2–3
years of initiation [12].
Castration-resistant prostate cancer (CRPC), previously
called hormone-resistant prostate cancer, is defined as pro-
gression of disease, either clinical or biochemical, in the
presence of castrate levels of circulating testosterone
(<50 ng/dL) [13, 14]. The understanding that the androgenarticle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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to further research and identification of therapeutic modal-
ities for this patient population.
The mechanisms by which hormone-sensitive prostate
cancer progresses to CRPC have been studied extensively.
They can be subcategorized into five general categories – AR
amplification and mutation, co-activator and co-repressor
modifications, aberrant activation/post-translational modi-
fication, altered steroidogenesis, and AR splice variants.
AR amplification, which allows continued androgen-axis
activation in the presence of low levels of androgens in
the prostate microenvironment, is found in 30–80 % of
CRPC cell lines [15, 16]. AR point mutations lead to in-
creased AR activity in the same microenvironment, but
also broaden the ligand pool to which AR responds, includ-
ing non-androgenic steroids [17–23]. Over 150 molecules
have been identified as co-activators and co-repressors to
the AR, and mutations in various components in the core-
gulator complex have been shown to improve androgen-
stimulated AR activation and lead to progression of diseaseFig. 1 Androgen receptor-dependent mechanisms of resistance in hormon
current FDA-approved therapies. wtAR, Wild-type androgen receptor; ARV
Testosterone; DHT, Dihydrotestosterone[24–27]. Aberrant activation encompasses pathways that
activate AR in a ligand-independent manner [28–30]. Alter-
ations in the steroidogenesis pathways allow prostate cancer
cells to bypass testosterone, and utilize adrenal andro-
gens to generate the functionally more potent DHT via
the 5α-dione pathway [31–35]. Androgen receptor splice
variants (ARV), which will be addressed in more detail
later, are constitutively active modifications of the wild
type AR. Figure 1 reviews the androgen axis and currently
approved therapies.
The treatment options for CRPC continue to grow.
Docetaxel, a well-known chemotherapeutic agent utilized
in the treatment of multiple malignancies, is a current
standard of care for this patient population, and for a long
time was the only option for treatment. However, with
research focusing on the mechanisms of progression to
CRPC, newer agents have been identified that target
those pathways specifically. The two approved medications,
enzalutamide (MDV, Xtandi) and abiraterone acetate
(Zytiga), work as an AR signaling inhibitor and a CYP17A1e-naïve prostate cancer leading to castration-resistance, and role of
, Androgen receptor variant; mutAR, Mutated androgen receptor; T,
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survival benefit they provide, the disease will continue to
progress.
Primary resistance is a problem in and of itself. Not all
treatment-naïve patients are responsive to their adminis-
tration. Approximately one third of patients treated with
abiraterone in the COU-AA-301 trial had radiographic
progression at 3 months [36] and one fourth of patients
treated with enzalutamide in the AFFIRM trial had radio-
graphic progression at 3 months [37], thereby demonstrat-
ing primary resistance. Of the patients who did respond,
survival benefit was 3.9 months and 4.8 months, re-
spectively; secondary progression eventually occurred by
24 months in virtually all patients despite initial benefit.
In an effort to understand the methods of targeting re-
sistance in metastatic CRPC, we will review the current
treatment modalities and the resistance mechanisms that
have been identified.
Current CRPC treatment modalities and target
areas for new therapies
Docetaxel and cabazitaxel
Docetaxel chemotherapy is a current standard of care
for patients with CRPC, based on the SWOG 9916 and
TAX327 trials, which demonstrated a 3-month survival
advantage of docetaxel therapy over mitoxantrone [38, 39].
Until recently, it was the primary option for CRPC pa-
tients, but with the approval of abiraterone and enzalu-
tamide, it is often not the first line therapy of choice.
However, the recent “ChemoHormonal therapy versus
androgen ablation randomized trial for extensive disease
in prostate cancer” (CHAARTED) trial, which was a phase
III randomized trial comparing docetaxel and ADT vs
ADT alone in hormone-naïve prostate cancer, has now
demonstrated the role for docetaxel as an initial treatment
option for hormone-naïve prostate cancer in conjunction
with ADT, providing a 17-month survival advantage [40].
This benefit was seen only in patients with high volume or
visceral metastases. At the American Society of Clinical
Oncology 2015 conference, James et al. presented the
initial results of the “Systemic Therapy in Advancing or
Metastatic Prostate Cancer: Evaluation of Drug Efficacy:
A Multi-Stage Multi-Arm Randomised Controlled Trial”
(STAMPEDE). In that trial, men with high-risk locally ad-
vanced or metastatic prostate cancer were randomized
to four arms – hormone therapy, hormone therapy +
docetaxel, hormone therapy + zoledronic acid, or hormone
therapy + docetaxel + zoledronic acid. At completion, add-
itional docetaxel added a 10-month survival benefit over
hormone therapy alone in this patient population, which
supports the findings of the CHAARTED trial [41].
Docetaxel is an anti-mitotic chemotherapeutic agent that
works by binding the β subunit of tubulin in microtubules,
thereby stabilizing the entire microtubule, preventingdepolymerization and inhibiting mitosis [42–44], which
induces apoptosis. It is a well-studied chemotherapeutic
agent, and there is a great deal of literature on the resist-
ance mechanisms towards docetaxel. Drug-efflux enables
resistance to docetaxel in multiple different malignancies,
including CRPC – multi-drug resistant proteins include
p-glycoprotein, multi-drug resistant protein 1, and breast
cancer resistance protein [45, 46]. Additionally, upregula-
tion of class III β-tubulin isoform in docetaxel-resistant
cell lines has been identified, since this isoform results in
less stable microtubules; inhibiting this isoform restored
docetaxel sensitivity [47–49]. However, targeting these
mechanisms is not widely applicable to CRPC.
Multiple prostate cancer-specific pathways have been
identified to contribute to docetaxel resistance, though
many have not resulted in any clinically targetable treat-
ments. A few of these pathways, however, are worth not-
ing. Docetaxel resistance has been linked to apoptosis
pathways, specifically upregulation of p53, an important
cell cycle regulator often found overexpressed in prostate
cancer, and activation of PAR1, which limits docetaxel-
induced apoptosis through NF-κB activation [50–52].
Docetaxel’s antimitotic activity itself induces survival
pathways in prostate cancer cells, such as the c-Jun N-
terminal kinase, which in turn leads to activation of
many transcription factors including STAT-1, STAT-3,
and NF-κB; knockdown models of these transcription
factors have been shown to be more docetaxel sensitive
[50, 53]. Over-expression of chaperone proteins such as
HSP27, HSP90, and clusterin have also been demon-
strated to contribute to docetaxel resistance. A second-
generation antisense drug, OGX-011, which inhibited
clusterin secretion, was tested in conjunction with do-
cetaxel in phase III trials, but did not meet its primary
endpoint [54–56].
In an effort to target docetaxel resistance, our lab
identified >1600 genes in taxane-resistant C42B cells
that had altered expression. Of the 52 % that were up-
regulated, we identified a member of the ATP-binding
cassette transporter family ABCB1 that was very highly
upregulated in taxane-resistant C42B cells but essentially
unchanged in taxane-sensitive cells. Inhibition of ABCB1
with ABCB1 shRNA resensitized taxane-resistant C42B
and DU-145 cells to docetaxel and enhanced apoptotic
cell death [52]. This was then confirmed with the use of
Elacridar, an ABCB1 inhibitor, in both cell lines. Api-
genen, a naturally occurring member in the flavone fam-
ily that was originally demonstrated to resensitize cells
to docetaxel chemotherapy [57], was found in our study
to downregulate ABCB1 expression in a dose-dependent
manner and reverse docetaxel resistance [52].
Cabazitaxel, a novel taxane approved for use in patients
with CRPC who have failed docetaxel chemotherapy, is
gaining traction in the treatment of CRPC. The TROPIC
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survival benefit compared to mitoxantrone in patients
with metastatic CRPC who had progressed on docetaxel
[58]. Besides the clinical importance of this result, it also
suggested that cabazitaxel had a novel mechanism of ac-
tion [59] and did not share the same resistance mecha-
nisms. Indeed, cabazitaxel was specifically selected for its
poor affinity for p-glycoprotein 1 due the latter’s noted
role in docetaxel resistance [60, 61].
Abiraterone acetate
Abiraterone acetate (Zytiga) is an irreversible inhibitor
of CYP17A1 that is structurally similar to pregnenolone.
CYP17A1 has two consecutive enzymatic functions in
the steroidogenesis pathway that contributes to the con-
version of pregnenolone to DHT, and its loss causes sig-
nificant loss of androgen production in the peripheral
organs, particularly in the production of adrenal androgens.
COU-AA-301, a multinational, randomized, double-blind
phase III trial of abiraterone in patients with metastatic
CRPC after docetaxel therapy, demonstrated a 3.9-monthFig. 2 Androgen synthesis pathway. Reproduced with permission from Clinsurvival benefit of abiraterone/prednisone over placebo/
prednisone. The subsequent COU-AA-302 trial established
abiraterone’s role in the pre-chemotherapy space for CRPC,
demonstrating a 4.4-month survival benefit [36, 62, 63].
However, as mentioned previously, approximately one-
third of all patients had primary resistance to abirater-
one use, and all patients with initial response eventually
progressed by 15 months [36].
Progression to CRPC includes utilization of the 5α-
dione pathway, which allows prostate cancer cells to by-
pass testosterone in the steroidogenesis pathway (Fig. 2),
leading to DHT production. However, CRPC cells are
still dependent on adrenal androgens such as dihydroe-
piandrosterone and its sulfated form, which are converted
to androstenedione in the prostate or adrenal gland by
3βHSD, an enzyme encoded by HSD3B. Androstenedione
is then converted to DHT via a two-step process using
5α-androstenedione as an intermediary, with the enzymes
17βHSD3 and AKR1C3 (encoded by HSD17B3 and
AKR1C3 respectively) mediating this conversion. By
targeting adrenal androgen production, abirateroneical Cancer Research [68]
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needed for intratumoral androgen production [64].
As can be expected, however, patients who develop re-
sistance to abiraterone demonstrate re-activation of intratu-
moral androgen production. Attard et al. [65] demonstrated
that inhibition of CYP17A1 actually led to increased levels
of the urinary metabolite 3α5α-17HP, which correlates with
the excretion of androsterone, which in turn is the primary
metabolite of 5α-reduced androgens such as DHT. The use
of abiraterone may therefore push 17-hydroxyprogesterone
towards the 5α-dione pathway.
Upregulation and mutations of the enzymes involved
in the steroidogenesis pathway likely contribute to the
progression to CRPC as well as resistance to abiraterone.
Chang et al. [66] demonstrated that the 1245C mutation
in HSD3B1, which was identified in treatment-naïve
CRPC, was also identified in abiraterone-resistant xeno-
graft models. Mostaghel et al. [67] demonstrated that
abiraterone-treated LuCaP cell lines had a 1.3- to 4.5-
fold increase in enzymes involved in the steroidogenesis
pathway, including CYP17A1, AKR1C3, HSD17B3, and
SDR5A2. Regulation of the steroidogenesis pathway is
complex. Our group identified IL-6, which is upregu-
lated in CRPC, as a mediator of increased expression of
steroidogenic enzymes including HSD3B2 and AKR1C3,
and IL-6 inhibition with small interfering RNA downreg-
ulated AKR1C3 expression [68]. AKR1C3 in particular is
a very important enzyme in the steroidogenesis pathway,
and its activation has been identified to contribute to
CRPC resistance in patients treated with abiraterone and
enzalutamide. There is a 16-fold increase of AKR1C3 in
enzalutamide-resistant C42B cell lines [69]. Knockdown
of AKR1C3 with shRNA or indomethacin, an AKR1C3
inhibitor, resensitized enzalutamide resistant cell lines to
enzalutamide therapy [69].
Enzalutamide
With the understanding that the androgen axis continues
to be active and play an important role in the progression
to CRPC, a new generation of AR signaling inhibitors are
being developed. The best-studied agent in this class, and
the only one approved for use, is enzalutamide (Xtandi,
ENZA, MDV-3100). As opposed to first-generation anti-
androgens, enzalutamide is an anti-androgen with mul-
tiple effects on AR – it is a competitive inhibitor of the
C-terminus ligand-binding domain, but it also prevents
AR nuclear translocation, AR binding to DNA, and co-
activator recruitment [44]. The AFFIRM III trial, a phase
III, double-blind, placebo-controlled trial in patients with
CRPC who had failed docetaxel, demonstrated a 4.8-
month survival benefit over placebo, and the subsequent
PREVAIL trial demonstrated enzalutamide’s effectiveness
in pre-chemotherapy CRPC patients [70, 71]. Just as in
the trials evaluating abiraterone, there is a subset ofpatients who have primary resistance to enzalutamide
therapy – in the AFFIRM trial, approximately 25 % of
patients progressed within the first 3 months of ther-
apy. By 24 months, all patients had progressed on enza-
lutamide [71].
Our lab has focused extensively on the process of au-
tophagy, one potentially important physiologic process
that may contribute to resistance to many therapies, in-
cluding enzalutamide, and may be an important adjunct-
ive target for treatment. Autophagy is a physiologic
catabolic process that is constitutively active at a basal
rate, but can be activated in response to stressors. When
activated, it utilizes lysosomal-mediated degradation of
cellular proteins and organelles to regenerate energy
[72–75]. Cancer cells can activate autophagy to prolong
survival under harsh conditions of metabolic stress in-
duced by various therapeutic modalities, but if pushed to
excessive or deregulated autophagy, this process can in-
duce type-II programmed cell death [76, 77]. ADT has
been demonstrated to induce autophagy, though the exact
mechanism is not yet known [78]. Inhibiting autophagy is
a potential target for adjunctive therapy, as we will discuss
later.
As enzalutamide also targets the ligand-binding domain
of AR, point mutations in this region can lead to second-
ary resistance as well. The Phe876Leu mutation has been
reported to make enzalutamide act more as an agonist
than an antagonist, but this has not yet been clinically
documented [79, 80]. Similar effects were noted for the
first-generation anti-androgens, so it can be inferred that
the same process is applicable for enzalutamide as well.
Another proposed mechanism is the “glucocorticoid
receptor take-over” pathway. Glucocorticoid receptors are
nuclear receptors similar in structure to AR, and gluco-
corticoids initially have a suppressive effect on prostate
cancer; they are often given in conjunction with early
treatments of CRPC. However, since the DNA binding do-
main (DNB) of the glucocorticoid receptor is very similar
to the DBD of AR [81, 82], and the glucocorticoid recep-
tor has been shown to bind to many AR regulated genes,
its upregulation in patients treated with chemotherapy or
ADT may contribute to enzalutamide resistance [83].
Androgen receptor splice variants (ARVs)
ARVs are truncated versions of the wild type AR that are
constitutively active. The truncated portion is typically
the C-terminal ligand-binding domain [84–87], though
at least one variant, ARV8, was reported to have loss of
the DNA binding domain [88]. The loss of the LBD makes
these variants ligand-independent. The true functional im-
plication of ARVs is not yet completely understood, as dir-
ect measurement of the variants has been limited by lack
of variant-specific antibodies, requiring proxy assessment
using transcribed RNA levels. However, transcribed RNA
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some degree of post-translational modification [85, 86].
The role of ARVs in clinical CRPC is being established
however. While some CRPC cell lines demonstrate low
levels of ARVs, CWR22Rv1 in particular demonstrates
almost equal levels of ARV and full-length AR [17].
Hornberg et al. [89] demonstrated that there were higher
levels of ARV expression in CRPC bone metastases
compared to hormone-sensitive prostate cancer bone me-
tastases, and that ARV expression was associated with
poorer prognosis.
Research in our lab, as well as others [90–92], strongly
support the role of ARV’s as mechanisms of resistance
in CRPC. As can be expected, the loss of the ligand-
binding domain removes the target of androgen-signaling
inhibitors such as enzalutamide, and CRPC is able to over-
come the loss of intratumoral androgens mediated by
abiraterone and anti-steroidogenesis agents. Li et al. [91]
demonstrated that knockdown of ARV7 in CWR22Rv1
cells restored responsiveness to anti-androgens, which
makes this an important target for future therapies. The
clinical significance of this is underscored by the findings
of Antonarakis et al. [93], who demonstrated that the
presence of ARV7 in circulating tumor cells in patients
treated with enzalutamide or abiraterone had a signifi-
cantly lower prostate-specific antigen (PSA) response,
shorter progression-free survival, and shorter overall
survival compared to men without ARV7. This is sup-
ported in the more recent work by Azad et al. [94], in
which pre-treatment AR gene aberration (copy number
increase and/or exon 8 deletion) on copy-free DNA was
predictive of poorer PSA response and shorter time to
radiographic/clinical progression. Indeed, this may con-
tribute to the primary resistance to enzalutamide and
abiraterone in the AFFIRM III and COU-AA-301 trials,
respectively. Interestingly, in recent data presented by
Antonarakis et al. [95], there was no significant differ-
ence in PSA response or progression-free survival in
patients treated with docetaxel regardless of ARV7 pres-
ence in circulating tumor cells. When comparing the
abiraterone and enzalutamide treated patients, the ARV7-
positive subset treated with docetaxel had better PSA re-
sponse and longer median progression-free survival [95].
This suggests that taxanes may be less susceptible to pri-
mary resistance in ARV7-positive patients, and therefore
may be a better option for initial treatment in patients
with known ARV7 expression.Emerging strategies
These various mechanisms of resistance to currently ap-
proved therapies of CRPC are each potential targets for
new therapies. Below, we focus on the emerging strat-
egies for identifying new management options.Our focus on autophagy has led to the identification
and assessment of various adjunctive medical therapies.
By utilizing autophagy inhibitors, such as clomipramine
and metformin, our group and others have demonstrated
effective cytotoxic results either as monotherapy or in
conjunction with known therapeutic agents. Specifically,
in the setting of CRPC, we demonstrated that clomipra-
mine and metformin significantly increased cytotoxicity in
in vitro and in vivo mouse models when used in conjunc-
tion with enzalutamide – the enzalutamide/clomipramine
combination decreased tumor volume by 91 %, the enza-
lutamide/metformin combination decreased it by 78 %,
while enzalutamide alone caused a 25–50 % decrease [74].
Ongoing clinical trials are exploring the adjunctive role of
metformin with enzalutamide therapy in CRPC patients.
Another important target is the NTD of the AR, which
has less than 15 % homology with the NTD of other
steroid receptors [96–98] and is important for transacti-
vation. As a preserved portion of the splice variant as
well as full-length AR, it has promise as a target for ther-
apy to address ligand-independent androgen axis activa-
tion. EPI-001, which is a small molecular NTD inhibitor,
has been evaluated by Sadar et al. [99, 100]. It func-
tioned as an effective and specific inhibitor of AR tran-
scriptional activity, even in the presence of increasing
androgen levels. As it targets the NTD, it was effective
at attenuating ARV activity in vitro and in vivo [100].
Along similar lines, AR degradation enhancers, such as
ASC-J9 developed by Chang et al. [101], target both
full-length AR and ARVs.
Our group has turned its attention to specific inhibi-
tors of the splice variants. Niclosamide, a currently ap-
proved anti-helminthic medication, was identified as an
inhibitor of ARV7 activity via multiple mechanisms. It
inhibited ARV7 transcriptional activity where enzaluta-
mide did not; it did so by reducing ARV7 recruitment to
the promoter regions of downstream targets. It also in-
hibits ARV7-specific protein expression and increases
protein degradation. MG132, a 26S proteasome inhibi-
tor, reduced niclosamide-mediated inhibition of ARV7
protein expression, suggesting that niclosamide induced
ARV degradation via a proteasome-dependent pathway.
In enzalutamide-resistant C42B cells expressing ARV7,
niclosamide was noted to have significant dose-dependent
cytotoxic effects. When used in conjunction with enzalu-
tamide, it demonstrated an additive response [102].
New techniques for identification of therapeutic agents
are also being developed. Drug-seq, a modification of
the ChIP-seq technology, utilizes a genome-wide binding
screen of a potential therapeutic agent in various physio-
logic conditions to identify potential therapeutic benefits.
In this manner, SD-70, a synthetic chemical in a molecular
library that was identified as an inhibitor of prostate can-
cer translocation events, was found to co-localize with
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manner. Functionally, it was determined to be a histone
demethylase inhibitor, with one of its targets being
KDM4C. It has been identified to have in vitro cyto-
toxic effects on hormone-sensitive LNCaP cells, C42B
and drug-resistant C42B cells, and in vivo efficacy in a
CWR22Rv1 mouse xenograft model [103].
In addition, there continues to be development of agents
that target the AR axis. These agents are briefly summa-
rized in Table 1 [104, 105]. They may have a role in the
treatment of CRPC either as monotherapy or in conjunc-
tion with some of the newer targets described.
Cross-resistance and sequencing of therapies
As more treatments become approved for CRPC, sequen-
cing these treatments becomes more problematic. Cross-
resistance has become evident, limiting use of these agents
in patients who have failed prior therapy. Cross-resistance
is unfortunately not limited to any one class of agents, but
rather seems to involve all the approved therapies for
CRPC.
Cheng et al. [106] demonstrated in a large retrospect-
ive study of 310 patients with metastatic CRPC patients
that prior abiraterone or docetaxel treatment blunted
subsequent enzalutamide response, confirming findings
from multiple smaller studies. PSA decline and PSA
progression-free survival were both significantly blunted
in patients who had been previously treated with abira-
terone, and less so in patients with prior docetaxel ther-
apy [106]. Other studies demonstrated similar findings
in men treated with docetaxel following abiraterone
[107, 108], and Nadal et al. [109] confirmed blunted effi-
cacy of enzalutamide in docetaxel-treated patients. Taxane
efficacy following AR targeted therapy is also blunted,
as demonstrated by van Soest et al. [110, 111] –Table 1 AR axis targeting drugs in clinical development
Agent Pharmaceutical company Mechanisms of action
ARN-509 Johnson & Johnson AR antagonist – inhib
DNA binding
AZD3514 Astra Zeneca Small molecule modu
mechanisms
EPI-001 ESSA Pharma Inc. Inhibiting the N-term
ODM-201 Bayer HealthCare AR antagonist – distin
OGX-011 (Custirsen) OncoGenex Pharmaceuticals
and Teva Pharmaceuticals
Second-generation an
a secreted protein th
is over-expressed in r
OGX427 (Apatorsen) OncoGenex Pharmaceuticals Second-generation an
TAK-700 (Orteronel) Takeda Pharmaceutical
Company
Non-steroidal imidazo
TOK-001 (Galeterone) Tokai Pharmaceuticals CYP17 lyase inhibitor
to the steroid-binding
VT-464 Viamet Pharmaceuticals Non-steroidal CYP17
independent of CYP1docetaxel inhibited tumor growth, AR nuclear trans-
location, AR regulated gene expression, and PSA levels
in enzalutamide-naïve tumors in castrated mice but not
in enzalutamide-resistant tumors. This cross-resistance
suggests that taxane therapy does in fact have a role in
AR axis modulation, inhibiting AR trafficking via microtu-
bules [112]. Importantly, however, the cross-resistance oc-
curs regardless of the sequencing of docetaxel and AR
targeted therapies.
Cross-resistance with AR targeted therapies and cabazi-
taxel appears to be less significant. As previously mentioned,
cabazitaxel was developed to overcome the resistance
to docetaxel mediated via P-glycoprotein [60]. It was
subsequently identified to have unique mechanisms of
actions compared to docetaxel [59], which may account
for why it does not have the same cross-resistance with
AR targeted therapies. van Soest et al. [110] concurrently
evaluated cabazitaxel efficacy in enzalutamide-naïve and
enzalutamide-resistant tumors in castrated mice and found
that cabazitaxel remained highly effective in enzalutamide-
resistant tumors, and more importantly, was much more
potent than docetaxel independent of the AR pathway. Al
Nakouzi et al. [113] confirmed similar findings in vivo and
in vitro. As a result, an ongoing clinical trial is evaluating
the role of cabazitaxel in chemotherapy-naïve CRPC
(FIRSTANA).
Cross-resistance has also pushed forward the need to
identify molecules that can inhibit resistance pathways
and emphasized the role of combination therapy. The
CHAARTED trial demonstrated the strength of combin-
ation therapy by providing the largest survival benefit of
any treatment regimen in advanced prostate cancer, by
treating patients with docetaxel and ADT [40, 114].
The agents identified above, such as the autophagy in-
hibitors metformin and clomipramine, the ARV7 inhibitor/target Current development status
its nuclear transportation, inhibits In multiple phase III clinical trials
(SPARTAN, etc.)
lating AR through two distinct Completed Phase I recruitment
inus of the AR protein Awaiting clinical development
ct from enzalutamide and ARN509 In phase III clinical trial (ARAMIS)
tisense drug that targets clusterin,
at acts as a cell-survival protein and
esponse to anti-cancer agents
In phase III clinical trials (AFFINITY)
tisense drug targeting HSP27 In phase II clinical trials
le inhibitor of CYP17A1 In phase III clinical trial
Competitive AR antagonist (binding
pocket of AR)
Phase III randomized control trial
(ARMOR3 trial)
lyase inhibitor AR antagonist activity
7 lyase inhibition
Phase II clinical trial
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ation promoter ASC-J9, and novel agents such as SD70, are
all important adjuncts to currently approved therapy. How-
ever, their efficacy may be compounded by utilization in
conjunction with approved therapies rather than as com-
petitive agents. SD70, as we demonstrated, had additive
cytotoxic effect when used with enzalutamide, abiraterone,
and docetaxel. As such, the future likely lies in novel com-
bination therapies rather than monotherapies.
Conclusions
CRPC is an incurable cancer characterized by progres-
sion despite multiple currently approved therapies. By
understanding the mechanisms of resistance to currently
approved treatments, targeted therapies can help overcome
these resistance pathways and provided clinical gains in the
treatment of this patient population. Combination therapy
may be the next advancement in the treatment of CRPC.
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